Gregory Schiffman has left his various senior executive positions at Affymetrix to take on the role of senior vice president and chief financial officer at Dendreon, a Seattle-based drug developer.
 
Affymetrix said last week that Schiffman resigned, effective immediately, from his posts as executive vice president, CFO, and treasurer, as well as other positions he holds at Affy subsidiaries.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.